stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Operating cash flow
CRISPR Therapeutics AG's operating cash flow for fiscal 2025 was −$345.0M, compared with −$142.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$374.6M. Over the past ten years it has ranged from −$495.7M (fiscal 2022) to $539.0M (fiscal 2021); the current reading is higher than 18% of that period. CRISPR Therapeutics AG ranks 583rd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$345.0M | — |
| FY2024 | −$142.8M | — |
| FY2023 | −$260.4M | — |
| FY2022 | −$495.7M | — |
| FY2021 | $539.0M | — |
| FY2020 | −$238.4M | — |
| FY2019 | $56.7M | — |
| FY2018 | −$96.2M | — |
| FY2017 | −$70.1M | — |
| FY2016 | −$55.3M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$89.7M | — |
| Jun 2026 | −$83.5M | — |
| Mar 2026 | −$108.9M | — |
| Dec 2025 | −$92.6M | — |
| 41 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $176.6M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$89.4M |
| ERAS Erasca, Inc. compare | −$98.0M |
| MANE Veradermics Incorporated compare | −$122.9M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.2M |
| EWTX Edgewise Therapeutics, Inc. compare | −$201.9M |
| COGT Cogent Biosciences, Inc. compare | −$307.5M |
| CRSP CRISPR Therapeutics AG | −$374.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement